



Published in final edited form as:

Cell Rep. 2022 November 08; 41(6): 111611. doi:10.1016/j.celrep.2022.111611.

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

Taejoon Won¹, Hannah M. Kalinoski², Megan K. Wood², David M. Hughes³, Camille M. Jaime⁴, Paul Delgado², Monica V. Talor¹, Ninaad Lasrado^{5,6}, Jay Reddy⁵, Daniela iháková^{1,2,7,*}

¹Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

²W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA

³Department of Chemical and Biomolecular Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD 21218, USA

⁴Graduate Program in Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

⁵School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA

⁶Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

⁷Lead contact

SUMMARY

Immune checkpoint inhibitors (ICIs) are an effective therapy for various cancers; however, they can induce immune-related adverse events (irAEs) as a side effect. Myocarditis is an uncommon, but fatal, irAE caused after ICI treatments. Currently, the mechanism of ICI-associated myocarditis is unclear. Here, we show the development of myocarditis in A/J mice induced by anti-PD-1 monoclonal antibody (mAb) administration alone without tumor cell inoculation, immunization, or viral infection. Mice with myocarditis have increased cardiac infiltration, elevated cardiac troponin levels, and arrhythmia. Anti-PD-1 mAb treatment also causes irAEs in other organs. Autoimmune T cells recognizing cardiac myosin are activated

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Correspondence: cihakova@jhmi.edu.

AUTHOR CONTRIBUTIONS

Conceptualization, T.W. and D.C.; methodology, formal analysis, and investigation, T.W., H.M.K., M.K.W., D.M.H., C.M.J., P.D., and M.V.T.; resources, N.L. and J.R.; writing – original draft, T.W. and D.C.; writing – review & editing, T.W., H.M.K., M.K.W., D.M.H., C.M.J., P.D., M.V.T., N.L., J.R., and D.C.; visualization, T.W., H.M.K., M.K.W., D.M.H., C.M.J., P.D., and M.V.T.; supervision, D.C.; funding acquisition, D.C.

DECLARATION OF INTERESTS

The authors declare no competing interests.

SUPPLEMENTAL INFORMATION


Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2022.111611>.

and increased in mice with myocarditis. Notably, cardiac myosin-specific T cells are present in naive mice, showing a phenotype of antigen-experienced T cells. Collectively, we establish a clinically relevant mouse model for ICI-associated myocarditis and find a contribution of cardiac myosin-specific T cells to ICI-associated myocarditis development and pathogenesis.

In brief

Won et al. demonstrate that PD-1 inhibitor treatment alone induces myocarditis in A/J mice, creating a mouse model for immune-checkpoint-inhibitor-associated myocarditis. Cardiac myosin-specific autoreactive T cells drive the pathogenesis of PD-1 inhibitor-induced myocarditis in mice. PD-1-expressing cardiac myosin-specific T cells are present in the heart during naive conditions.

Graphical Abstract



INTRODUCTION

In the last decade, immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 have become a groundbreaking therapy to effectively treat various types of cancers such as melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, and urothelial carcinoma.^{1,2} However, over 70% of patients with cancer treated with ICIs experienced immune-related adverse events (irAEs) in the heart, lung, liver, intestine, and skin, ranging from mild to severe grades.³⁻⁵ Myocarditis occurring in ICI-treated patients with cancer is an uncommon irAE but is fatal, with a 40% reported

mortality rate.⁶ Patients with ICI-associated myocarditis present chest pain, cardiac troponin level elevation, and abnormality on electrocardiogram (ECG), echocardiogram, or cardiac magnetic resonance imaging, and the clinical presentations may vary between cases.⁷⁻¹¹ Histologically, infiltrating cells in ICI-associated myocarditis were composed of mostly T cells and macrophages, showing the predominance of CD8⁺ T cells over CD4⁺ T cells.¹⁰⁻¹⁴ Since PD-1 and CTLA-4 are expressed mainly in T cells, researchers speculated that T cells play a crucial role in the development of ICI-associated myocarditis.¹⁵ However, it is unclear whether ICI-associated myocarditis is caused by autoimmune T cells recognizing cardiac antigens or off-target effects of anti-tumor T cells by cross-reactivity.

Previous animal studies have shown cardiotoxicity of inhibition of the PD-1/PD-L1 pathway, but there were no appropriate mouse models that completely mimic the human ICI-associated myocarditis. PD-1 blockade by neutralizing antibody worsened the severity of myocarditis induced by cardiac myosin peptide immunization or CVB3 infection.^{16,17} PD-1-deficient mice have been used for studying ICI-associated myocarditis; however, to induce spontaneous development of myocarditis, PD-1-deficient (*Pdcd1*^{-/-}) C57BL/6 mice necessitated additional conditions such as crossing to autoimmune-prone MRL mice, introducing a haploinsufficient *Ctla4* gene, or using genetically engineered T cells.¹⁸⁻²¹ *Pdcd1*^{-/-} mice on BALB/c background spontaneously developed myocarditis and dilated cardiomyopathy mediated by an anti-cardiac troponin I (cTnI) autoantibody, which is a distinct mechanism from ICI-associated myocarditis.^{22,23} To better understand the etiology and pathogenesis of ICI-associated myocarditis, a proper mouse model established on the immunocompetent strain is needed.

Cardiac myosin is a heart antigen recognized by autoantibodies in patients with myocarditis and dilated cardiomyopathy.²⁴⁻²⁷ Cardiac myosin peptides have the capacity to stimulate T cells isolated from patients with myocarditis.²⁸ Animal studies support the involvement of cardiac myosin as a potent heart-specific autoantigen stimulating T cells during myocarditis. Immunization with cardiac myosin or its shortened peptide caused experimental autoimmune myocarditis (EAM) development in mice, exhibiting elevated anti-myosin autoantibody levels and increased myosin-specific T cells.²⁹⁻³¹

In this study, we induced ICI-associated myocarditis in A/J mice, an immunocompetent strain, only by injecting PD-1 neutralizing monoclonal antibody (mAb). Autoimmune inflammation was also found in other organs such as the lung, colon, skeletal muscle, and pancreas of PD-1 inhibitor-treated mice. We suggest cardiac myosin as a potential target of pathogenic T cells in ICI-associated myocarditis. Mice with PD-1 inhibitor-induced myocarditis showed an increased number of cardiac-myosin-specific T cells in the heart. We also found the presence of PD-1-expressing myosin-specific T cells in naive mice, suggesting activation of heart antigen-reactive T cells by PD-1 inhibitor as a possible mechanism of ICI-associated myocarditis.

RESULTS

α PD-1 mAb treatment induces multiorgan irAEs in mice

To establish whether PD-1 blockade can cause irAEs in immunocompetent mice, we injected α PD-1 mAb (clone RMP1–14) into A/J mice every 3 days for 21 days. Control mice were treated with rat immunoglobulin G2a (IgG2a) isotype Abs. We found that the α PD-1 mAb treatment led to inflammation in multiple organs such as the heart, lung, colon, skeletal muscle, and pancreas by histologic analysis, while isotype controls showed no significant inflammation in all tested organs (Figure 1A). The incidence of autoimmune inflammation by PD-1 blockade differed between organs, ranging from 19% in the heart to 53% in the colon (Figure 1B; Table S1). Most mice with cardiac infiltration simultaneously developed autoimmune inflammation in other organs (Table S1). No significant infiltrations were noted in the thyroid, kidney, and ankle joint of mice treated with α PD-1 mAb or isotype control. In the blood, we found that PD-1 blockade led to a reduction in CD62L⁺CD44⁻ naive subset with a corresponding increase of the CD62L⁺CD44⁺ memory subset in CD8⁺ T cells compared with isotype control (Figures 1C and 1D). The proportion of the CD62L⁻CD44⁺ effector CD8⁺ T cell subset was also increased in α PD-1 mAb-treated mice but was not significant (Figure S1A). Peripheral CD4⁺ T cells had increased proportions of CD62L⁺CD44⁺ memory cells in the PD-1 blockade group, while naive and effector CD4⁺ T cells were comparable between α PD-1 mAb and isotype controls (Figures 1C, 1E, and S1B). These results indicate that PD-1 inhibitor treatment can lead to multiorgan irAEs associated with activated T cells in mice.

PD-1 blockade leads to ICI-associated myocarditis development in mice

Several reports have shown that patients with ICI-associated myocarditis had elevated cTnI levels, arrhythmia, and cardiac infiltration of T cells and CD68⁺ myeloid cells.^{7,8,11,12,14} Thus, we investigated whether myocarditis resulting from PD-1 inhibitor treatment in mice recapitulates human ICI-associated myocarditis. Myocarditic mice had mild to severe infiltrations throughout the entire heart including the ventricle, atrium, pericardium, and endocardium (Figure 2A). For further examination, we divided α PD-1 mAb-treated mice into two subgroups—mice with or without myocarditis development, hereafter called α PD-1 myocarditis and α PD-1 control, respectively (Figure 2B). Myocarditis development and severity were assessed by histological analysis (Figure 2B). Flow cytometry analysis confirmed a significant increase of infiltrating CD45⁺ cells in the hearts with α PD-1 myocarditis compared with isotype and α PD-1 control groups (Figure 2C). Furthermore, in the α PD-1 myocarditis group, three mice with the most cardiac CD45⁺ cell numbers exhibited an abnormal ECG trace, while all isotype and α PD-1 control mice preserved normal electrical activity (Figure 2D). The flow cytometry analysis revealed a significantly higher number of CD8⁺ T cells, CD4⁺ T cells, monocytes, macrophages, and natural killer (NK) cells in the hearts with α PD-1 myocarditis than those of other groups (Figure 2E). The ratio of CD8⁺ to CD4⁺ T cells was also increased in the hearts with α PD-1 myocarditis compared with isotype and α PD-1 controls, suggesting the predominance of CD8⁺ T cells during PD-1 inhibitor-induced myocarditis (Figure 2F). Cardiac B cell number was increased after PD-1 inhibitor treatment regardless of myocarditis development compared with the isotype control (Figure 2G). The number of $\gamma\delta$ T cells

and neutrophils was comparable between all groups (Figure S2A). Elevated serum cTnI levels suggested cardiac damage in mice with α PD-1 myocarditis, confirmed by increased apoptotic cardiomyocytes in the TUNEL assay (Figures 2H and S2B). Next, to test if the incidence of PD-1 inhibitor-induced myocarditis can be increased by supplementation with adjuvant or other immunotherapy, we treated mice with complete Freund's adjuvant (CFA), α CTLA-4 mAb (clone UC-10-4F10-11), or recombinant interleukin (IL)-12p70, in addition to α PD-1 mAb. All tested supplements raised the incidence of myocarditis induced by PD-1 blockade, and IL-12 was the most potent among them (Figure 2I). Without PD-1 inhibitor treatment, recombinant IL-12 alone was sufficient to induce a mild level of myocarditis in mice at the incidence of 20%, while mice treated with CFA or α CTLA-4 mAb alone did not develop myocarditis (Figure S2C). To determine if this model can be used in other immunocompetent mouse strains, we treated C57BL/6 and BALB/c mice with α PD-1 mAb for 21 days. Unlike A/J mice, those mice did not exhibit significant myocarditis development. Collectively, our findings indicate that α PD-1 mAb treatment causes myocarditis development in A/J mice, recapitulating human ICI-associated myocarditis.

Cardiac T cells are highly activated during PD-1 inhibitor-induced myocarditis

As shown in Figure 2E, mice with PD-1 inhibitor-induced myocarditis showed increased numbers of both CD8⁺ and CD4⁺ T cells in the hearts compared with other groups. We tested if cardiac T cells exhibit an activated and pathogenic phenotype and gene-expression profile in mice with α PD-1 myocarditis. CD62L⁻CD44⁺ effector cell subsets of both CD8⁺ and CD4⁺ T cells in the α PD-1 myocarditis group were proportionally increased compared with isotype and α PD-1 controls (Figures 3A and 3B). Similarly, the absolute number of effector CD8⁺ and CD4⁺ T cells was significantly increased in mice with α PD-1 myocarditis (Figure S3A). In addition, we found that CD69 expression, an activation marker, on cardiac T cells was upregulated in mice with α PD-1 myocarditis (Figure 3C). Gene-expression profiles revealed that cardiac CD8⁺ T cells in the α PD-1 myocarditis group expressed a higher level of *Ifng* (interferon [IFN]- γ), *Tnf* (tumor necrosis factor [TNF]- α), *Prf1* (perforin), and *Gzmb* (granzyme B) than that of isotype and α PD-1 controls (Figure 3D). Similarly, CD4⁺ T cells in the hearts with α PD-1 myocarditis showed upregulated *Ifng* mRNA expression (Figure 3E). It is well known that highly activated T cells express immune checkpoint molecules such as CTLA-4 and PD-1 as compensatory regulation.³² We examined the expression of immune checkpoint molecules on cardiac T cells by flow cytometry. Cardiac CD8⁺ T cells expressing both TIM-3 and PD-1 or only TIM-3 were increased in mice with α PD-1 myocarditis compared with isotype and α PD-1 controls (Figures 3F and 3G). Cell frequency of PD-1 single-positive CD8⁺ T cells was comparable between groups (Figures 3F and 3G). In comparison, cardiac CD4⁺ T cells revealed an increase of subsets expressing both TIM-3 and PD-1 or only PD-1 compared with other groups (Figures 3F and 3G). There was no proportional difference in TIM3⁺PD-1⁻ CD4⁺ T cells between groups (Figures 3F and 3G). The absolute number of all CD8⁺ and CD4⁺ subpopulations—TIM-3⁻PD-1⁺, TIM-3⁺PD-1⁺, and TIM-3⁺PD-1⁻—was significantly increased in the α PD-1 myocarditis group compared with isotype and α PD-1 controls (Figure S3B). Supportively, we found that cardiac T cell expression of immune checkpoint transcripts such as *Pdcd1* (PD-1), *Havcr2* (TIM-3), and *Ctla4* (CTLA-4) was significantly upregulated

in mice with α PD-1 myocarditis compared with other groups (Figures 3H and 3I). These data suggest that PD-1 blockade can activate pathogenic T cells in the heart, leading to the development of myocarditis.

Cardiac-myosin-specific T cells are associated with PD-1 inhibitor-induced myocarditis

Cardiac myosin is one of the autoantigens related to myocarditis onset and progress in humans and mice.^{24,25,28–31} To test if T cell autoimmunity against cardiac antigens contributes to ICI-associated myocarditis, we searched for cardiac-myosin-specific T cells in the heart with α PD-1 myocarditis using α -myosin heavy chain (Myhc) peptide-major histocompatibility complex (MHC) tetramers. CD8⁺ T cells and CD4⁺ T cells were stained with Myhc_{338–348}-MHC class I tetramers and Myhc_{334–352}-MHC class II tetramers, respectively.^{31,33,34} In the hearts with α PD-1 myocarditis, the number of cardiac-myosin-specific autoimmune CD8⁺ and CD4⁺ T cells was significantly increased compared with isotype and α PD-1 control groups (Figures 4A and 4B). Cardiac-myosin-specific and bystander T cells in the α PD-1 myocarditis group showed an activated phenotype (CD62[–]CD44⁺CD69⁺) at a comparable level; however, transcript profiles revealed that cardiac-myosin-specific CD8⁺ T cells expressed a higher level of *Ifng*, *Prf1*, and *Gzmb* genes than that of bystander T cells during α PD-1 myocarditis (Figure 4C). Myosin-specific CD4⁺ T cells also showed elevated *Ifng* expression (Figure 4D). Additionally, we found that genes related to immune checkpoint molecules such as *Pdcd1*, *Havcr2*, and *Ctla4* were upregulated in cardiac-myosin-specific autoimmune CD8⁺ T cells compared with non-myosin-specific bystander T cells (Figure 4E). Cardiac-myosin-specific CD4⁺ T cells showed an increased mRNA expression level of *Pdcd1* and *Ctla4* but not for the *Havcr2* gene (Figure 4F). To confirm the pathogenicity of myosin-specific T cells in myocarditis, we adoptively transferred myosin peptide-primed T cells into sublethally irradiated mice that were treated with α PD-1 mAb after the transfer. Myosin-primed CD4⁺ T cell donors were isolated from spleens of mice immunized with Myhc_{334–352} peptide, while control CD4⁺ T cell donors were isolated from naive mouse spleens. Both myosin-primed T cells and control T cells were pulsed with Myhc_{334–352} peptide *in vitro* and adoptively transferred to the recipients. Using the histologic and flow cytometric analyses, we found that all mice that received myosin-pulsed CD4⁺ T cells developed myocarditis 18 days after the adoptive transfer (Figures 4G, 4H, 4I, and S4A). The number of cardiac CD4⁺ T cells, monocytes, and macrophages was significantly increased in the recipients of myosin-primed CD4⁺ T cells compared with the control group (Figure S4B). In contrast, no recipients in the control T cell group developed myocarditis. Honjo and his colleagues have previously reported that PD-1-deficient BALB/c mice spontaneously developed inflammatory dilated cardiomyopathy mediated by anti-cTnI autoantibodies.^{22,23} In our mice with α PD-1 myocarditis, the serum level of anti-cTnI or cardiac myosin Abs was comparable or slightly elevated compared with the isotype and α PD-1 control groups, suggesting a limited role of anti-heart antigen autoantibodies in α PD-1 myocarditis (Figure S4C). Collectively, PD-1 inhibitor treatment leads to the activation of autoimmune T cells specific for cardiac myosin during ICI-associated myocarditis.

PD-1-expressing cardiac-myosin-specific T cells are present in naive mice

To understand how PD-1 inhibitor treatment initiates the development of myocarditis, we examined the presence of cardiac-myosin-specific autoimmune T cells and their PD-1 expression in naive mice. We found that 1%–2% of CD8⁺ and CD4⁺ T cells in the naive heart, mediastinal lymph node (medLN), and spleen exhibited a specificity to cardiac myosin (Figures 5A, 5B, and S5A). In all tested organs, cardiac-myosin-specific CD4⁺ T cells expressed a higher level of PD-1 compared with non-myosin-specific T cells (Figures 5C and 5D). Within the myosin-specific CD4⁺ T cells of naive organs, PD-1-expressing cells showed a greater proportion of effector- or memory-like phenotype (CD44⁺CD69⁺) compared with the PD-1⁻ counterpart, suggesting their quick response to PD-1 inhibitor treatment (Figures 5E and 5F). In the CD8⁺ T cells in the heart and medLN, the PD-1 expression level was comparable between cardiac-myosin-specific and non-myosin-specific cells, while cardiac-myosin-specific CD8⁺ T cells in the spleen showed a higher PD-1 expression than their non-myosin-specific counterpart (Figures S5B and S5C). However, PD-1⁺ cardiac-myosin-specific CD8⁺ T cells showed an increased CD44⁺CD69⁺ compartment compared with PD-1⁻ myosin-specific cells (Figures S5D and S5E). To study the factors affecting the number of myosin-specific autoimmune T cells, we compared cardiac T cell profiles in aged or female mice with young adult males. First, we found that naive aged mice had a significantly higher number of myosin-specific CD8⁺ T cells in the heart compared with young adults, while myosin-specific CD4⁺ T cells were comparable between aged and young mice (Figures 5G and 5H). In the spleen, aged and young mice had a comparable number of myosin-specific CD8⁺ T cells. Second, male and female mice showed no differences in the number of both CD8⁺ and CD4⁺ myosin-specific autoimmune T cells in the heart (Figure S5F). In addition, we found that cardiac-myosin-specific CD8⁺ and CD4⁺ T cells were present in the blood of naive mice as well as in the heart, medLN, and spleen. To investigate whether the number of circulating myosin-specific T cells is associated with PD-1 inhibitor-induced myocarditis development, we collected blood T cells prior to αPD-1 mAb treatment. In the retrospective analysis after 21 days of PD-1 blockade, the number of circulating myosin-specific T cells in the αPD-1 myocarditis group showed no differences from the isotype or αPD-1 control group (Figure S5G). These data suggest that cardiac-myosin-specific autoimmune T cells are present in the naive heart or other organs and can be rapidly activated upon PD-1 inhibitor treatment.

DISCUSSION

In this study, we established a mouse model for ICI-associated myocarditis and showed cardiac-myosin-specific autoreactive T cells to be an important mediator. 19% of A/J mice injected with PD-1 inhibitor developed myocarditis as assessed by histology and flow cytometry analysis, showing serum cTnI level elevation and ECG abnormality similar to human ICI-associated myocarditis. We also found the predominance of CD8⁺ T cells over CD4⁺ T cells in cardiac inflammatory cells of mice with myocarditis. We administrated αPD-1 mAb (clone RMP1–14) into A/J mice with no additional procedures such as immunization, viral infection, or tumor cell inoculation. By far, no mouse models for spontaneous development of ICI-associated myocarditis induced by PD-1 inhibitor alone in an immunocompetent mouse strain have been reported. In a recent study, PD-1 inhibitor

treatment induced myocardial T cell infiltration and cardiac dysfunction in C57BL/6 mice bearing tumors.³⁵ However, those mice showed no signs of local T cell accumulation and cardiomyocyte death, indicating a milder severity of myocarditis than that of our model. A/J mice are widely used to investigate the pathogenesis of autoimmune or viral myocarditis.^{29,36–39} Aged A/J mice are known to develop skeletal muscle dystrophy, hearing loss, and cancer spontaneously, but autoimmune inflammation in the heart or other organs has not been reported.^{40–42} We used 8- to 12-week-old and 44-week-old mice that showed no cancer development in any organs after α PD-1 mAb treatment or isotype controls.

Besides myocarditis, we found that PD-1 inhibitor treatment caused irAEs in various organs. It has been reported that mice with PD-1 blockade using neutralizing Abs or genetic manipulation developed autoimmune inflammation in the lung, colon, and pancreas.^{43–45} However, these mice were on an MRL or NOD background that is predisposed to autoimmune disorders and are not considered an immunocompetent strain. Thus, our approach of inducing myocarditis development using PD-1 inhibitor treatment in A/J mice can be a clinically relevant animal model for human ICI-associated myocarditis and potentially other irAEs including pneumonia, colitis, myositis, and pancreatitis. In addition, our α PD-1 mAb treatment approach has an advantage over the genetic deletion of PD-1 expression, avoiding further manipulations during the developmental stage. CTLA-4-deficient mice died of lethal myocarditis and pancreatitis by 3–4 weeks of age; however, conditional CTLA-4 ablation in mature adult mice using a tamoxifen-inducible Cre system was not lethal.^{46,47} The adult mice conditionally lacking CTLA-4 expression developed autoimmune inflammation in the heart and pancreas, but its incidence and severity were lower than those of congenital *CTLA-4*^{-/-} mice.⁴⁷

The mechanism of ICI-associated myocarditis onset and progress is unclear. In an early case report of ICI-associated myocarditis, melanoma patients treated with ipilimumab, a CTLA-4 inhibitor, and nivolumab, a PD-1 inhibitor, presented an expansion of shared T cell clones in the myocardium and tumor, suggesting the contribution of T cells targeting both heart and tumor antigens to myocarditis development.¹⁴ However, it has not been addressed which antigens are responsible for activating pathogenic T cells in ICI-associated myocarditis and where they originate—the heart or tumor. In our study, PD-1 inhibitor treatment alone was sufficient to induce myocarditis development in mice and did not require tumor cells. This indicates that autoreactive T cells targeting cardiac antigens, rather than tumor antigens, could play a crucial role in ICI-associated myocarditis. Using the tetramer staining assay, we found that cardiac myosin was a target of highly activated pathogenic T cells in mice with PD-1 inhibitor-induced myocarditis. Immunization with myosin purified from mouse hearts or its shortened peptide is a well-established method to induce autoimmune myocarditis in various mouse strains.³⁸ Mice with CVB3 infection-induced myocarditis also revealed increased anti-cardiac myosin Ab levels in the serum and generation of myosin-specific T cells in the spleen and lymph nodes.^{48,49} In our current study, we showed that the adoptive transfer of cardiac-myosin-pulsed CD4⁺ T cells caused acute myocarditis development in mice, as we previously have shown.⁵⁰ Supportively, it has been reported that transgenic mice expressing T cell receptors specific for cardiac myosin developed spontaneous myocarditis between 2 and 6 weeks of age.⁵¹ Given the elevated level of anti-cardiac myosin autoantibody in patients with acute myocarditis and its sequela

dilated cardiomyopathy, the autoimmune response against cardiac myosin is proposed as an important mechanism of community-acquired myocarditis.^{52,53} Thus, cardiac-myosin-specific autoimmune T cells might be a potential mediator in ICI-associated myocarditis.

Activated T cells express immune checkpoint molecules including PD-1 and CTLA-4 to induce T cell exhaustion in the periphery as a negative regulatory mechanism.³² In our mouse model for ICI-associated myocarditis, PD-1 neutralizing mAb treatment might block inhibitory signaling in cardiac-myosin-specific autoimmune T cells, causing persistent T cell activation shown by highly upregulated cytokine and immune checkpoint molecule expression. PD-L1, a ligand for PD-1, is expressed by both hematopoietic and non-hematopoietic cells.² In the mouse heart, cardiomyocytes and endothelial cells express PD-L1 to protect from pathogenic T cell immune responses.^{17,43,54} We have previously reported that loss of graft endothelial PD-L1 expression was significantly associated with CD8⁺ T cell infiltration in patients with heart transplantation.⁵⁵ Similar to the PD-1 inhibitor, PD-L1 inhibitor treatment has led to ICI-associated myocarditis in patients with cancer.^{56,57}

Given that IL-12 supplementation increased the incidence of PD-1 inhibitor-induced myocarditis in our study, IL-12 could play an important role in the pathogenesis of ICI-associated myocarditis. Other animal studies showed that IL-12 receptor signaling was required for the initiation and progress of autoimmune and viral myocarditis.^{58–61} As a suggested mechanism, IL-12 enhanced the differentiation of pathogenic effector CD8⁺ T cells causing lethal myocarditis when adoptively transferred into mice.⁶² In both clinical and preclinical settings, anti-tumor T cell activity induced by PD-1 blockade became more effective when combined with IL-12 treatment.^{63,64}

To address how ICI treatment is involved in myocarditis onset, we first sought cardiac-myosin-specific T cells in naive A/J mice. Our tetramer assay showed that myosin-specific T cells were present in naive mouse heart, medLN, and spleen. This is supported by the finding that autoreactive T cells recognizing cardiac myosin avoided the negative selection during the thymic developmental stage in mice and humans due to a lack of Myhc gene (*Myh6*) expression in medullary thymic epithelial cells.⁶⁵ Second, we found that there was a PD-1-expressing subpopulation among cardiac-myosin-specific autoimmune T cells in naive mouse tissues. A proportion of those PD-1⁺ cardiac-myosin-specific T cells exhibited a phenotype of CD44 and CD69 co-expression. PD-1, CD44, and CD69 are well-known activation markers expressed in effector, central memory, or tissue-resident memory T cells, which have already been exposed to antigens.^{66–68} Taken together, we suggest that PD-1 inhibitor treatment may re-activate cardiac-myosin-experienced T cells by blocking the regulatory signaling, leading to ICI-associated myocarditis development. Further investigation using a high-dimensional single-cell analysis is needed to identify and comprehensively characterize autoimmune T cells recognizing heart antigens.

The determinant of ICI-associated myocarditis onset and progress is also unclear. Our study showed that only a small subgroup of A/J mice developed myocarditis. In humans, the incidence of ICI-associated myocarditis is about 1% among patients with cancer treated with ICIs.¹⁵ In our mouse model, the number of most cardiac immune cell populations including myosin-specific T cells was increased only in the α PD-1 myocarditis group, but

not in the α PD-1 control group, compared with the isotype control group. This suggests that ICI treatment could induce the development of myocarditis only in individuals with a sufficient number of activated cardiac-myosin-specific autoimmune T cells. Some studies have reported molecular mimicry between cardiac myosin and microbes in T cell targets, indicating the highly variable number and characteristics of cardiac-myosin-specific T cells between individuals due to different environmental conditions.^{69,70} In this study, we tested only cardiac myosin as an autoantigen responsible for ICI-associated myocarditis development. However, there are other well-known heart antigens such as β 1-adrenergic receptor, muscarinic M2 receptor, and Na-K-ATPase, recognized by autoantibodies in patients with myocarditis and dilated cardiomyopathy.^{71,72} This suggests that multiple different autoimmune targets could be involved in ICI-associated myocarditis. Meanwhile, most mice with myocarditis in our study developed autoimmune inflammation in other organs at the same time, resembling patients who had two or more irAEs after ICI treatment.⁷³ This may be explained by the concurrent activation of multiple T cell clones targeting different tissue-specific antigens upon ICI treatment but also by the activation of a single autoimmune T cell clone recognizing a common antigen throughout organs including the heart. In our study, there were α PD-1 mAb-treated mice that did not develop myocarditis but revealed irAEs in one or more other organs, suggesting the independent activation of T cell clones targeting other organs from myosin-specific T cells.

In our study, α PD-1 mAb treatment caused myocarditis development in A/J mice but not in C57BL/6 and BALB/c mice, suggesting that genetic or phenotypic differences between those strains may contribute to the activation of autoreactive T cells in the heart. Despite being considered an immunocompetent strain, A/J mice lack complement C5 expression due to genetic defect, unlike C5-sufficient C57BL/6 and BALB/c mice.⁷⁴ The C5 deficiency in A/J mice led to a higher susceptibility to *Mycobacterium tuberculosis* or *Listeria monocytogenes* infection compared with C57BL/6 mice.^{75,76} In addition, the MHC haplotype expressed in A/J mice is H-2^a, different from that of C57BL/6 (H-2^b) and BALB/c (H-2^d) mice. The human leukocyte antigen (HLA) polymorphism has been suggested as a genetic risk associated with the pathogenesis of inflammatory dilated cardiomyopathy.⁷⁷ Thus, C5 deficiency and MHC haplotype of A/J mice would be associated with increased susceptibility to myocarditis upon PD-1 inhibitor treatment.

Our data revealed that aging affected the increased number of myosin-specific CD8⁺ T cells in the heart, suggesting a higher risk of PD-1 inhibitor-related myocarditis in the elderly. This is supported by a report describing an increased risk of ICI-associated myocarditis in patients aged 75 years or older.⁷⁸ However, unlike in the heart, the number of myosin-specific CD8⁺ T cells in aged mouse spleen was not increased, indicating that peripheral T cells may not reflect the autoreactive T cell context of the heart. Our retrospective analysis revealed that mice with α PD-1 mAb-induced myocarditis had no outstanding myosin-specific T cell counts in the circulation compared with control mice before α PD-1 mAb treatment. Thus, the anatomic distribution of myosin-specific autoimmune T cells could be an important factor contributing to ICI-associated myocarditis as well as senescence. Meanwhile, in many autoimmune diseases, the activation of the innate immune system is considered to trigger the disease, driving further activation of adaptive immunity.⁷⁹ Interestingly, PD-1 can be expressed in innate immune cells such

as macrophages, dendritic cells, and innate lymphoid cells during diseased conditions, playing a regulatory role.^{80–82} Macrophages and monocytes were a predominant population in cardiac infiltration of our mouse model and patients with ICI-associated myocarditis, suggesting the pathogenic activation of the innate immune system directly by ICI treatment as well as T cell activation.^{11,12,14} In this study, the crucial role of autoreactive T cells, a part of the adaptive immune system, in ICI-associated myocarditis was shown using PD-1 inhibitor treatment and adoptive T cell transfer approaches. More studies will be necessary to address the role of innate immunity in ICI-associated myocarditis.

In conclusion, we generated a clinically relevant mouse model for ICI-associated myocarditis by administrating α PD-1 mAb into the A/J mouse strain. Mice with ICI-associated myocarditis showed increased T cells, macrophages, and monocytes in the heart and elevated serum cTnI levels. ECG abnormality was found in mice with very severe ICI-associated myocarditis. α PD-1 mAb-treated mice also developed irAEs in other organs. We found that the number and activity of cardiac-myosin-specific T cells were increased in mice with α PD-1 mAb-induced myocarditis, indicating a contribution of heart autoantigen-reactive T cells to ICI-associated myocarditis. In addition, the presence of PD-1⁺ cardiac myosin-specific T cells in naive mice suggests that ICI treatment could re-activate heart autoantigen-experienced T cells, which are under control by the PD-1/PD-L1 pathway in naive conditions, leading to myocarditis development.

Limitations of the study

In this study, mice were treated with α PD-1 or isotype mAb for 21 days. No earlier or later time points were tested, limiting the understanding of the entire time course of ICI-associated myocarditis in our model. The contribution of tumor cells to ICI-associated myocarditis was not tested in our study because there are no syngeneic tumor cell lines available for A/J mice. In the adoptive transfer experiment, we used T cells isolated from myosin peptide-immunized mice as a donor, resulting in myocarditis development in all recipients. Myosin-specific T cells directly sorted from naive mice using tetramer staining were also tested for T cell adoptive-transfer-induced myocarditis. Due to the limited cell number, even after *in vitro* expansion, we were only able to adoptively transfer those T cells to three recipient mice, which developed myocarditis with a 33% incidence. This limits our understanding of the pathogenicity of myosin-specific T cells under naive conditions, which are more clinically relevant than in immunization with cardiac myosin peptide. We showed that A/J mice aged 44 weeks had an increased number of myosin-specific autoreactive T cells in the heart; however, myocarditis induction in those old mice by α PD-1 mAb treatment was not conducted due to the limited number of mice.

STAR★METHODS

RESOURCE AVAILABILITY

Lead contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Daniela íháková (cihakova@jhmi.edu).

Materials availability—This study did not generate new unique reagents.

Data and code availability—All data reported in this paper will be shared by the lead contact upon request.

This paper does not report original code.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice—Wild-type male A/J mice (strain #000646) were purchased from the Jackson Laboratory. Mice were housed in specific pathogen-free animal facilities at the Johns Hopkins University School of Medicine. Experiments were conducted with 8- to 12-week-old age-matched male mice. Thirty-six mice were injected with anti-PD-1 mAb (150 µg/mouse, clone RMP1-14, Bio X Cell) intraperitoneally every three days for 21 days. As a control, 25 mice were injected with rat IgG2a isotype mAb (Bio X Cell). Mice were supplemented with CFA (MilliporeSigma), anti-CTLA-4 mAb (clone UC-10-4F10-11, Bio X Cell), or recombinant murine IL-12p70 (PeproTech) when indicated. CFA was emulsified by mixing with the same volume of PBS and subcutaneously injected into the flank of mice (100 µL/mouse) on days 0 and 7. Anti-CTLA-4 mAb (150 µg/mouse) or IL-12p70 (300 ng/mouse) was intraperitoneally injected every three days. In senescence or sex difference experiments, 44-week-old male mice or 8- to 12-week-old female mice were used. All methods and protocols were approved by the Animal Care and Use Committee of the Johns Hopkins University.

METHOD DETAILS

Histology study—All harvested tissues were fixed, paraffin-embedded, cut as 4-µm-thick sections, and stained with H&E. Myocarditis severity was assessed by microscopic assessment and shown as the percentage of inflamed area in the heart section. Inflammation in other organs was assessed as increased cellularity in parenchymal space of the lung, lamina propria in the colon, or quadriceps in the right hind limb compared to naïve mouse organs. Pancreatitis was assessed in the entire tissue section, not limited to islets. Grading was performed by two independent blinded investigators. Images were acquired on a BX43 microscope (Olympus) with a DS-Fi3 camera (Nikon) using NIS-Elements D Software (Nikon).

Electrocardiography—Mice were terminally anesthetized by intraperitoneal injection with Avertin (0.4 mg/g). Electrode on right lower limb was connected to ground. Other three limbs' electrodes were sequentially changed to obtain bipolar leads following standard human EKG pattern: Lead I (DI) trace - positive electrode on left upper limb and negative electrode on right upper limb; Lead II (DII) trace - positive electrode on right upper limb and negative electrode on left lower limb; Lead III (DIII) trace - positive electrode on left upper limb and negative lead on left lower limb, creating standard Einthoven's triangle. We used a bipolar polygrapher (DigiMed) running DMSI-400 software.

Single cell isolation—Hearts were minced using a razor blade and then incubated with 5 mL of tissue digestion enzyme solution for 30 minutes at 37°C with agitation. The digestion enzyme solution was prepared with 600 U/ml Collagenase (Worthington), 50 U/ml DNase I (Worthington), and 50 U/ml Hyaluronidase (MilliporeSigma). After incubation with digestion enzymes, tissues were dissociated using gentleMACS Dissociator (Miltenyi). Cells were washed and filtered through 40 µm cell strainers (Falcon). Spleen and lymph node cells were mechanically dissociated from tissues using frosted-end glass slides. PBMCs were isolated using density gradient centrifugation.

Flow cytometry—Heart cells were stained with viability marker Live/Dead Fixable Aqua (Thermo Fisher) and then Fc-blocked with anti-CD16/32 mAb (Thermo Fisher) and normal rat serum (Thermo Fisher). Next, cells were surface-stained with fluorochrome-conjugated antibodies against CD45, NKp46, CD11b, Ly6G, F4/80, CD64, Ly6C, CD19, CD3, TCRγδ, CD4, CD8, CD62L, CD44, CD69, PD-1, and TIM-3 (BioLegend or BD Biosciences). For tetramer staining, cells were stained with Myhc_{338–348}-H-2D^d and Myhc_{334–352}-I-A^k tetramers or HIV_{P18-110}-H-2D^d and human CLIP_{87–101}-I-A^k tetramers as a control before viability marker staining. Dr. Jay Reddy (University of Nebraska-Lincoln) and NIH Tetramer Core Facility kindly provided tetramers. Sample acquisition was performed on a BD LSR II or LSRFortessa flow cytometer (BD) running FACSDiva (BD). Results were analyzed using FlowJo software (BD). For FACS sorting, BD FACSAria IIu Cell Sorter was used.

ELISA—For determining cTnI levels in mouse serum, we used ELISA kit according to the manufacturer's instruction (Life Diagnostics). For anti-cardiac myosin and cTnI IgG ELISA, microplates were coated with 0.5 µg/mL cardiac myosin peptide (DSAFDVLSTAEKAGVYK) or cTnI peptide (VDKVDDEERYDVEAKVTKN) overnight at 4°C, washed, and incubated with mouse serum for 2 hours at room temperature. Microplates were washed, incubated with secondary anti-mouse IgG antibody (Abcam), and developed with alkaline phosphatase (Bio-Rad). Optical density was read at 405 nm (Molecular Devices).

TUNEL assay—To detect apoptotic cells in the heart, we stained tissue sections with TUNEL according to the manufacturer's instruction (Promega). Mouse heart slides were deparaffinized, rehydrated, fixed, and permeabilized. After equilibration, slides were probed with fluorescein-12-dUTP using terminal deoxynucleotidyl transferase (TdT). The slides were counterstained with DAPI to visualize all nuclei. Images were acquired using LSM 700 microscope (Zeiss).

Real-time RT-PCR—Total RNA from FACS-sorted cells was extracted using RNeasy Plus Micro Kit (Qiagen). Single-stranded cDNA was synthesized with iScript Reverse Transcription Supermix (Bio-Rad). Target genes were amplified using PowerUP SYBR Green PCR Master Mix (Applied Biosystems), and real-time cycle thresholds were detected via MyiQ2 thermal cycler (Bio-Rad). Data were analyzed by the 2^{-Ct} method and were normalized to *HPRT* expression and then to biological controls.

Adoptive transfer of T cells—CD4⁺ T cells primed with cardiac myosin peptide were adoptively transferred into recipient mice to induce myocarditis, as previously published.⁵⁰ Donor mice were immunized with Myhc_{334–352} peptide on days 0 and 7. Spleen cells were isolated on day 14 and then *in vitro* stimulated with 50 µg/mL Myhc_{334–352} peptide, 20 ng/mL recombinant IL-23, 10 ng/mL recombinant IL-1β, and 40 mM NaCl. As a control, spleen cells from naïve mice were stimulated in the same manner. After four days of *in vitro* culture, CD4⁺ T cells were sorted using magnetic beads-labeled Ab (Miltenyi) and intravenously injected into mice irradiated with 500 cGy γ-radiation (1×10⁶ cells/recipient). All recipients were treated with 150 µg of anti-PD-1 mAb every three days, and their hearts were harvested 18 days after T cell transfer to evaluate myocarditis development. Where indicated, as donor cells, Myhc_{334–352} tetramer-positive CD4⁺ T cells were FACS-sorted from naïve mouse spleens and *in vitro* expanded with anti-CD3 and CD28 antibodies (2.5 µg/mL each). Tetramer-negative CD4⁺ T cells were also sorted and *in vitro* stimulated to serve as a control. Those T cells were adoptively transferred to irradiated recipients that were treated with anti-PD-1 mAb after transfer.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistics—GraphPad Prism 9 software was used for statistical analysis. Data were analyzed using Student's *t*-test or one-way ANOVA followed by Tukey's multiple comparison test. Statistically significant comparisons were represented by asterisks: *, *p* < 0.05; **, *p* < 0.005; ***, *p* < 0.0005; ****, *p* < 0.0001.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This work was supported by the American Heart Association (AHA) 19TPA34910007 and 20TPA35490421, the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) R01HL118183 and R01HL136586, and the Global Autoimmune Institute. T.W. is supported by the 2018 Rhett Lundy Memorial Research Fellowship from the Myocarditis Foundation. M.K.W. is funded by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) F31AR077406. D.M.H. is funded by the NIH/NHLBI F31HL149328. C.M.J. is funded by the AHA Diversity Supplement Award 961456. We thank the NIH Tetramer Core Facility (contract number 75N93020D00005) for providing the tetramers used in this study.

INCLUSION AND DIVERSITY

We support inclusive, diverse, and equitable conduct of research.

REFERENCES

1. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, and Merghoub T. (2022). Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. *Nat. Rev. Clin. Oncol* 19, 37–50. 10.1038/s41571-021-00552-7. [PubMed: 34580473]
2. Bagchi S, Yuan R, and Engleman EG (2021). Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. *Annu. Rev. Pathol* 16, 223–249. 10.1146/annurev-pathol-042020-042741. [PubMed: 33197221]

3. Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr., and Calabrese L. (2020). Moving towards personalized treatments of immune-related adverse events. *Nat. Rev. Clin. Oncol* 17, 504–515. 10.1038/s41571-020-0352-8. [PubMed: 32246128]
4. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al. (2019). Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat. Rev. Clin. Oncol* 16, 563–580. 10.1038/s41571-019-0218-0. [PubMed: 31092901]
5. Song P, Zhang D, Cui X, and Zhang L. (2020). Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. *Thorac. Cancer* 11, 2406–2430. 10.1111/1759-7714.13541. [PubMed: 32643323]
6. Herrmann J. (2020). Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. *Nat. Rev. Cardiol* 17, 474–502. 10.1038/s41569-020-0348-1. [PubMed: 32231332]
7. Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, Salem JE, Wu SM, Moslehi JJ, and Zhu H. (2021). Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. *Annu. Rev. Pharmacol. Toxicol* 61, 113–134. 10.1146/annurev-pharmtox-010919-023451. [PubMed: 32776859]
8. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, Alexandre J, Rassaf T, Mueller OJ, Aras M, et al. (2021). Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. *JAMA Cardiol.* 6, 1329–1337. 10.1001/jamacardio.2021.2241. [PubMed: 34232253]
9. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, and Zippelius A. (2015). Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. *J. Immunother. Cancer* 3, 11. 10.1186/s40425-015-0057-1. [PubMed: 25901283]
10. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, and Luke JJ (2016). Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. *J. Immunother. Cancer* 4, 50. 10.1186/s40425-016-0152-y. [PubMed: 27532025]
11. Tadokoro T, Keshino E, Makiyama A, Sasaguri T, Ohshima K, Katano H, and Mohri M. (2016). Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. *Circ. Heart Fail* 9, e003514. 10.1161/CIRCHEARTFAILURE.116.003514. [PubMed: 27650418]
12. Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, and Mertz KD (2016). Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. *J. Immunother. Cancer* 4, 13. 10.1186/s40425-016-0117-1. [PubMed: 26981243]
13. Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, and Haydon A. (2017). Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. *Br. J. Cancer* 117, 921–924. 10.1038/bjc.2017.253. [PubMed: 28797029]
14. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. (2016). Fulminant myocarditis with combination immune checkpoint blockade. *N. Engl. J. Med* 375, 1749–1755. 10.1056/NEJMoa1609214. [PubMed: 27806233]
15. Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, and Kitis RN (2021). Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. *J. Clin. Invest* 131, 145186. 10.1172/JCI145186. [PubMed: 33645548]
16. Tsuruoka K, Wakabayashi S, Morihara H, Matsunaga N, Fujisaka Y, Goto I, Imagawa A, and Asahi M. (2020). Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. *Int. J. Cardiol* 313, 67–75. 10.1016/j.ijcard.2020.04.033. [PubMed: 32402518]
17. Seko Y, Yagita H, Okumura K, Azuma M, and Nagai R. (2007). Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. *Cardiovasc. Res* 75, 158–167. 10.1016/j.cardiores.2007.03.012. [PubMed: 17434153]
18. Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, and Okazaki T. (2010). PD-1 deficiency results in the development of fatal myocarditis in MRL mice. *Int. Immunol* 22, 443–452. 10.1093/intimm/dxq026. [PubMed: 20410257]

19. Wei SC, Meijers WC, Axelrod ML, Anang NAAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, et al. (2021). A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. *Cancer Discov.* 11, 614–625. 10.1158/2159-8290.CD-20-0856. [PubMed: 33257470]
20. Tarrío ML, Grabie N, Bu DX, Sharpe AH, and Lichtman AH (2012). PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. *J. Immunol* 188, 4876–4884. 10.4049/jimmunol.1200389. [PubMed: 22491251]
21. Nishimura H, Nose M, Hiai H, Minato N, and Honjo T. (1999). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity* 11, 141–151. 10.1016/s1074-7613(00)80089-8. [PubMed: 10485649]
22. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, and Honjo T. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. *Science* 291, 319–322. 10.1126/science.291.5502.319. [PubMed: 11209085]
23. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, and Honjo T. (2003). Auto-antibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. *Nat. Med* 9, 1477–1483. 10.1038/nm955. [PubMed: 14595408]
24. Lauer B, Schannwell M, Kuehl U., Strauer, B.E., and Schultheiss, H.P. (2000). Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. *J. Am. Coll. Cardiol* 35, 11–18. 10.1016/s0735-1097(99)00485-4. [PubMed: 10636253]
25. Neumann DA, Burek CL, Baughman KL, Rose NR, and Herskowitz A. (1990). Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. *J. Am. Coll. Cardiol* 16, 839–846. 10.1016/s0735-1097(10)80331-6. [PubMed: 2229805]
26. Mascaro-Blanco A, Alvarez K, Yu X, Lindenfeld J, Olansky L, Lyons T, Duvall D, Heuser JS, Gosmanova A, Rubenstein CJ, et al. (2008). Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. *Autoimmunity* 41, 442–453. 10.1080/08916930802031579. [PubMed: 18781470]
27. Fairweather D, Petri MA, Coronado MJ, and Cooper LT (2012). Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. *Expert Rev. Clin. Immunol* 8, 269–284. 10.1586/eci.12.10.
28. Myers JM, Cooper LT, Kem DC, Stavrakis S, Kosanke SD, Shevach EM, Fairweather D, Stoner JA, Cox CJ, and Cunningham MW (2016). Cardiac myosin-Th17 responses promote heart failure in human myocarditis. *JCI Insight* 1, 85851. 10.1172/jci.insight.85851. [PubMed: 27366791]
29. Donermeyer DL, Beisel KW, Allen PM, and Smith SC (1995). Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. *J. Exp. Med* 182, 1291–1300. 10.1084/jem.182.5.1291. [PubMed: 7595200]
30. Pummerer CL, Luze K, Grassl G, Bachmaier K, Offner F, Burrell SK, Lenz DM, Zamborelli TJ, Penninger JM, and Neu N. (1996). Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. *J. Clin. Invest* 97, 2057–2062. 10.1172/JCI118642. [PubMed: 8621795]
31. Massilamany C, Upadhyaya B, Gangaplara A, Kuszynski C, and Reddy J. (2011). Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers. *BMC Immunol.* 12, 40. 10.1186/1471-2172-12-40. [PubMed: 21767394]
32. Waldman AD, Fritz JM, and Lenardo MJ (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat. Rev. Immunol* 20, 651–668. 10.1038/s41577-020-0306-5. [PubMed: 32433532]
33. Massilamany C, Gangaplara A, Basavalingappa RH, Rajasekaran RA, Khalilzad-Sharghi V, Han Z, Othman S, Steffen D, and Reddy J. (2016). Localization of CD8 T cell epitope within cardiac myosin heavy chain-alpha334–352 that induces autoimmune myocarditis in A/J mice. *Int. J. Cardiol* 202, 311–321. 10.1016/j.ijcard.2015.09.016. [PubMed: 26422020]
34. Basavalingappa RH, Arumugam R, Lasrado N, Yalaka B, Massilamany C, Gangaplara A, Riethoven JJ, Xiang SH, Steffen D, and Reddy J. (2020). Viral myocarditis involves the generation of autoreactive T cells with multiple antigen specificities that localize in lymphoid and non-

- lymphoid organs in the mouse model of CVB3 infection. *Mol. Immunol* 124, 218–228. 10.1016/j.molimm.2020.06.017. [PubMed: 32615275]
35. Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, et al. (2022). Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. *Eur. Heart J* 43, 316–329. 10.1093/eurheartj/ehab430. [PubMed: 34389849]
 36. Rose NR, Wolfgram LJ, Herskowitz A, and Beisel KW (1986). Post-infectious autoimmunity: two distinct phases of coxsackievirus B3-induced myocarditis. *Ann. N. Y. Acad. Sci* 475, 146–156. 10.1111/j.1749-6632.1986.tb20864.x. [PubMed: 3024549]
 37. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, and Craig SW (1987). Cardiac myosin induces myocarditis in genetically predisposed mice. *J. Immunol* 139, 3630–3636. [PubMed: 3680946]
 38. Ciháková D, Sharma RB, Fairweather D, Afanasyeva M, and Rose NR (2004). Animal models for autoimmune myocarditis and autoimmune thyroiditis. *Methods Mol. Med* 102, 175–193. 10.1385/1-59259-805-6:175.
 39. Göser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R, Zittrich S, Blaudeck N, Hardt SE, Pfitzer G, et al. (2006). Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. *Circulation* 114, 1693–1702. 10.1161/CIRCULATIONAHA.106.635664. [PubMed: 17015788]
 40. Ho M, Post CM, Donahue LR, Lidov HGW, Bronson RT, Goolsby H, Watkins SC, Cox GA, and Brown RH Jr. (2004). Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. *Hum. Mol. Genet* 13, 1999–2010. 10.1093/hmg/ddh212. [PubMed: 15254015]
 41. Keithley EM, Canto C, Zheng QY, Fischel-Ghodsian N, and Johnson KR (2004). Age-related hearing loss and the ahl locus in mice. *Hear. Res* 188, 21–28. 10.1016/S0378-5955(03)00365-4. [PubMed: 14759567]
 42. Hoag WG (1963). Spontaneous cancer in mice. *Ann. N. Y. Acad. Sci* 108, 805–831. 10.1111/j.1749-6632.1963.tb13421.x. [PubMed: 14081516]
 43. Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, and Kelley VR (2008). Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. *J. Immunol* 181, 2513–2521. 10.4049/jimmunol.181.4.2513. [PubMed: 18684942]
 44. Adam K, Iuga A, Tocheva AS, and Mor A. (2021). A novel mouse model for checkpoint inhibitor-induced adverse events. *PLoS One* 16, e0246168. 10.1371/journal.pone.0246168. [PubMed: 33571254]
 45. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, and Honjo T. (2005). Establishment of NOD-Pdcd1^{-/-} mice as an efficient animal model of type I diabetes. *Proc. Natl. Acad. Sci. USA* 102, 11823–11828. 10.1073/pnas.0505497102. [PubMed: 16087865]
 46. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, and Sharpe AH (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* 3, 541–547. 10.1016/1074-7613(95)90125-6. [PubMed: 7584144]
 47. Klocke K, Sakaguchi S, Holmdahl R, and Wing K. (2016). Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. *Proc. Natl. Acad. Sci. USA* 113, E2383–E2392. 10.1073/pnas.1603892113. [PubMed: 27071130]
 48. Gangaplara A, Massilamany C, Brown DM, Delhon G, Pattnaik AK, Chapman N, Rose N, Steffen D, and Reddy J. (2012). Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-alpha-reactive CD4 T cells in A/J mice. *Clin. Immunol* 144, 237–249. 10.1016/j.clim.2012.07.003. [PubMed: 22854287]
 49. Latif N, Zhang H, Archard LC, Yacoub MH, and Dunn MJ (1999). Characterization of anti-heart antibodies in mice after infection with coxsackie B3 virus. *Clin. Immunol* 91, 90–98. 10.1006/clim.1998.4679. [PubMed: 10219259]
 50. Wu L, Diny NL, Ong S, Barin JG, Hou X, Rose NR, Talor MV, and Ciháková D. (2016). Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice. *Eur. J. Immunol* 46, 582–592. 10.1002/eji.201545924. [PubMed: 26660726]

51. Nindl V, Maier R, Ratering D, De Giuli R, Zust R, Thiel V, Scandella E, Di Padova F, Kopf M, Rudin M, et al. (2012). Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. *Eur. J. Immunol* 42, 2311–2321. 10.1002/eji.201142209. [PubMed: 22730043]
52. Nussinovitch U, and Shoenfeld Y. (2013). The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. *Clin. Rev. Allergy Immunol* 44, 98–108. 10.1007/s12016-010-8229-8. [PubMed: 21207194]
53. Caforio ALP, Mahon NJ, Tona F, and McKenna WJ (2002). Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. *Eur. J. Heart Fail* 4, 411–417. 10.1016/s1388-9842(02)00010-7. [PubMed: 12167378]
54. Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH, and Lichtman AH (2007). Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. *Circulation* 116, 2062–2071. 10.1161/CIRCULATIONAHA.107.709360. [PubMed: 17938288]
55. Bracamonte-Baran W, Gilotra NA, Won T, Rodriguez KM, Talor MV, Oh BC, Griffin J, Wittstein I, Sharma K, Skinner J, et al. (2021). Endothelial stromal PD-L1 (programmed death ligand 1) modulates CD8(+) T-cell infiltration after heart transplantation. *Circ. Heart Fail* 14, e007982. 10.1161/CIRCHEARTFAILURE.120.007982. [PubMed: 34555935]
56. Berner AM, Sharma A, Agarwal S, Al-Sam S, and Nathan P. (2018). Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. *Eur. J. Cancer* 101, 287–290. 10.1016/j.ejca.2018.06.021. [PubMed: 30017380]
57. Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, Szwebel TA, Kramkimmel N, Lethrosne C, Bruch JF, et al. (2018). Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. *Neurology* 91, e985–e994. 10.1212/WNL.0000000000006124. [PubMed: 30089619]
58. Afanasyeva M, Wang Y, Kaya Z, Stafford EA, Dohmen KM, Sadighi Akha AA, and Rose NR (2001). Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. *Circulation* 104, 3145–3151. 10.1161/hc5001.100629. [PubMed: 11748115]
59. Frisancho-Kiss S, Nyland JF, Davis SE, Frisancho JA, Barrett MA, Rose NR, and Fairweather D. (2006). Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rbeta1 signaling and IFN-gamma increase inflammation in males independent from STAT4. *Brain Res.* 1126, 139–147. 10.1016/j.brainres.2006.08.003. [PubMed: 16949558]
60. Eriksson U, Kurrer MO, Sebald W, Brombacher F, and Kopf M. (2001). Dual role of the IL-12/IFN-gamma axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-gamma. *J. Immunol* 167, 5464–5469. 10.4049/jimmunol.167.9.5464. [PubMed: 11673566]
61. Fairweather D, Frisancho-Kiss S, Yujung SA, Barrett MA, Davis SE, Steele RA, Gatewood SJL, and Rose NR (2005). IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart. *J. Immunol* 174, 261–269. 10.4049/jimmunol.174.1.261. [PubMed: 15611248]
62. Grabie N, Delfs MW, Westrich JR, Love VA, Stavrakis G, Ahmad F, Seidman CE, Seidman JG, and Lichtman AH (2003). IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. *J. Clin. Invest* 111, 671–680. 10.1172/JCI16867. [PubMed: 12618521]
63. Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al. (2018). Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. *Immunity* 49, 1148, 1161.e7. 10.1016/j.immuni.2018.09.024. [PubMed: 30552023]
64. Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, et al. (2020). Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. *Clin. Cancer Res* 26, 2827–2837. 10.1158/1078-0432.CCR-19-2217. [PubMed: 32376655]
65. Lv H, Havari E, Pinto S, Gottumukkala RVSRK, Cornivelli L, Raddassi K, Matsui T, Rosenzweig A, Bronson RT, Smith R, et al. (2011). Impaired thymic tolerance to alpha-myosin directs

- autoimmunity to the heart in mice and humans. *J. Clin. Invest* 121, 1561–1573. 10.1172/JCI44583. [PubMed: 21436590]
66. Montacchiesi G, and Pace L. (2022). Epigenetics and CD8(+) T cell memory. *Immunol. Rev* 305, 77–89. 10.1111/imr.13057. [PubMed: 34923638]
 67. Baaten BJG, Tinoco R, Chen AT, and Bradley LM (2012). Regulation of antigen-experienced T cells: lessons from the quintessential memory marker CD44. *Front. Immunol* 3, 23. 10.3389/fimmu.2012.00023. [PubMed: 22566907]
 68. Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, and Ahmed R. (2018). Role of PD-1 during effector CD8 T cell differentiation. *Proc. Natl. Acad. Sci. USA* 115, 4749–4754. 10.1073/pnas.1718217115. [PubMed: 29654146]
 69. Gil-Cruz C, Perez-Shibayama C, De Martin A, Ronchi F, van der Borght K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, et al. (2019). Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. *Science* 366, 881–886. 10.1126/science.aav3487. [PubMed: 31727837]
 70. Massilamany C, Gangaplara A, Steffen D, and Reddy J. (2011). Identification of novel mimicry epitopes for cardiac myosin heavy chain- α that induce autoimmune myocarditis in A/J mice. *Cell. Immunol* 271, 438–449. 10.1016/j.cellimm.2011.08.013. [PubMed: 21939961]
 71. Yoshikawa T, Baba A, and Nagatomo Y. (2009). Autoimmune mechanisms underlying dilated cardiomyopathy. *Circ. J* 73, 602–607. 10.1253/circj.cj-08-1151. [PubMed: 19246813]
 72. Kallwellis-Opara A, Dörner A, Poller WC, Noutsias M, Kühl U, Schultheiss HP, and Pauschinger M. (2007). Autoimmunological features in inflammatory cardiomyopathy. *Clin. Res. Cardiol* 96, 469–480. 10.1007/s00392-007-0524-x. [PubMed: 17503113]
 73. Xie X, Wang L, Li Y, Xu Y, Wu J, Lin X, Lin W, Mai Q, Chen Z, Zhang J, et al. (2022). Multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study. *Front. Immunol* 13, 879900. 10.3389/fimmu.2022.879900. [PubMed: 35924238]
 74. Wetsel RA, Fleischer DT, and Haviland DL (1990). Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. *J. Biol. Chem* 265, 2435–2440. [PubMed: 2303408]
 75. Jagannath C, Hoffmann H, Sepulveda E, Actor JK, Wetsel RA, and Hunter RL (2000). Hypersusceptibility of A/J mice to tuberculosis is in part due to a deficiency of the fifth complement component (C5). *Scand. J. Immunol* 52, 369–379. 10.1046/j.1365-3083.2000.00770.x. [PubMed: 11013008]
 76. Gervais F, Stevenson M, and Skamene E. (1984). Genetic control of resistance to *Listeria monocytogenes*: regulation of leukocyte inflammatory responses by the Hc locus. *J. Immunol* 132, 2078–2083. [PubMed: 6699408]
 77. Meder B, Rühle F, Weis T, Homuth G, Keller A, Franke J, Peil B, Lorenzo Bermejo J, Frese K, Hüge A, et al. (2014). A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. *Eur. Heart J* 35, 1069–1077. 10.1093/eurheartj/eh251. [PubMed: 23853074]
 78. Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, and Ishizawa K. (2019). Factors associated with immune checkpoint inhibitor-related myocarditis. *JAMA Oncol.* 5, 1635–1637. 10.1001/jamaoncol.2019.3113. [PubMed: 31436802]
 79. Root-Bernstein R, and Fairweather D. (2015). Unresolved issues in theories of autoimmune disease using myocarditis as a framework. *J. Theor. Biol* 375, 101–123. 10.1016/j.jtbi.2014.11.022. [PubMed: 25484004]
 80. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, and Ayala A. (2009). PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. *Proc. Natl. Acad. Sci. USA* 106, 6303–6308. 10.1073/pnas.0809422106. [PubMed: 19332785]
 81. Yao S, Wang S, Zhu Y, Luo L, Zhu G, Flies S, Xu H, Ruff W, Broadwater M, Choi IH, et al. (2009). PD-1 on dendritic cells impedes innate immunity against bacterial infection. *Blood* 113, 5811–5818. 10.1182/blood-2009-02-203141. [PubMed: 19339692]

82. Mallett G, Laurence A, and Amarnath S. (2019). Programmed cell death-1 receptor (PD-1)-Mediated regulation of innate lymphoid cells. *Int. J. Mol. Sci* 20, E2836. [10.3390/ijms20112836](https://doi.org/10.3390/ijms20112836).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Highlights

- PD-1 inhibitor treatment alone causes myocarditis development in A/J mice
- Cardiac-myosin-specific T cells drive PD-1 inhibitor-induced myocarditis in mice
- Cardiac-myosin-specific autoimmune T cells are present in naive mouse hearts
- Cardiac-myosin-specific autoimmune T cells express PD-1 during naive conditions




Figure 1. α PD-1 mAb treatment induces irAEs in multiple organs in mice

(A) Representative images of H&E staining on hearts, lungs, colons, skeletal muscles, and pancreases from α PD-1 mAb-treated A/J mice and isotype controls. Scale bars: 100 μ m.

(B) Pie charts showing the incidence of inflammation in hearts, lungs, colons, skeletal muscles, and pancreases after α PD-1 mAb treatment.

(C) Flow cytometry analysis of CD62L and CD44 expression in peripheral blood mononuclear cell (PBMC) CD8⁺ and CD4⁺ T cells from α PD-1 mAb-treated mice and isotype controls.

(D and E) Cell frequency of naive ($CD62L^+CD44^-$) and memory ($CD62L^+CD44^+$) subsets in PBMC $CD8^+$ T cells (D) and memory subset in PBMC $CD4^+$ T cells (E) from mice with α PD-1 mAb or isotype Ab treatment.

Pooled data of two experiments are shown. Student's t test was used for statistical analysis.

* $p < 0.05$; ** $p < 0.005$.




Figure 2. αPD-1 mAb treatment causes ICI-associated myocarditis in mice

(A) Representative images of H&E staining on right atrium (RA), left ventricle (LV), pericardium (P), and endocardium (E) from αPD-1 mAb-treated A/J mice and isotype controls. Arrows indicate P. Scale bars: 100 (black) or 800 μm (gray). (B and C) Myocarditis development assessed by histology (B) and flow cytometry analysis (B and C). αPD-1 mAb-treated mice were divided into two subgroups by histologic observation—myocarditis development (αPD-1 myocarditis) and no myocarditis (αPD-1 control). Number of CD45⁺ infiltrating cells in hearts was assessed by flow cytometry.

- (D) Electrocardiogram trace of mice with α PD-1 myocarditis and isotype controls.
- (E) Number of cardiac CD8⁺ T cells (CD3⁺CD8⁺), CD4⁺ T cells (CD3⁺CD4⁺), monocytes (CD11b⁺ Ly6G⁻F4/80⁺Ly6C⁺), macrophages (CD11b⁺Ly6G⁻ F4/80⁺CD64⁺Ly6C⁻), and NK cells (NKp46⁺) in α PD-1 myocarditis, α PD-1 control, and isotype control mice.
- (F) Ratio of CD8⁺ T cells to CD4⁺ T cells in hearts of α PD-1 myocarditis, α PD-1 control, and isotype control mice.
- (G) Number of B cells (CD19⁺) in mouse hearts of α PD-1 myocarditis, α PD-1 control, and isotype control groups.
- (H) Serum cTnI levels in α PD-1 myocarditis, α PD-1 control, and isotype control mice.
- (I) Incidence of myocarditis in mice treated with α PD-1 mAb alone or in combination with CFA, α CTLA-4 mAb, or IL-12.
- Pooled data of two or three experiments are shown. One-way ANOVA with Tukey's test was used for statistical analysis. * $p < 0.05$; ** $p < 0.005$; *** $p < 0.0005$; **** $p < 0.0001$.




Figure 3. Cardiac T cells are activated in mice with PD-1 inhibitor-induced myocarditis
 (A and B) Flow cytometry analysis (A) and cell frequencies (B) of effector (CD62L⁻CD44⁺), memory (CD62L⁺CD44⁺), and naive (CD62L⁺CD44⁻) cells in cardiac CD8⁺ and CD4⁺ T cells from αPD-1 mAb-treated mice and isotype controls. αPD-1 mAb-treated mice were divided into two subgroups—myocarditis development (αPD-1 myocarditis) and no myocarditis (αPD-1 control).
 (C) Cell frequency of CD69⁺ T cells in hearts of αPD-1 myocarditis, αPD-1 control, and isotype control mice.

(D and E) Gene expression of cardiac CD8⁺ (D) and CD4⁺ (E) T cells in α PD-1 myocarditis, α PD-1 control, and isotype control groups. CD8⁺ and CD4⁺ T cells were fluorescence-activated cell sorted (FACS) from heart cells.

(F and G) Flow cytometry analysis (F) and cell frequencies (G) of TIM-3⁻PD-1⁺, TIM-3⁺PD-1⁺, and TIM-3⁺PD-1⁻ cells in CD8⁺ and CD4⁺ T cells from hearts of α PD-1 myocarditis, α PD-1 control, and isotype control mice.

(H and I) Gene expression of FACS cardiac CD8⁺ (H) and CD4⁺ (I) T cells from α PD-1 myocarditis, α PD-1 control, and isotype control mice.

Pooled data of two or three experiments are shown in (A)–(C), (F), and (G). Representative data of two independent experiments are shown as mean values in (D), (E), (H), and (I).

One-way ANOVA with Tukey's test was used for statistical analysis. * $p < 0.05$; ** $p < 0.005$; *** $p < 0.0005$; **** $p < 0.0001$.




Figure 4. T cells specific for cardiac myosin contribute to PD-1 inhibitor-induced myocarditis (A and B) Flow cytometry analysis (A) and cell frequencies (B) of cardiac myosin-MHC tetramer-positive cells in CD8⁺ and CD4⁺ T cells of αPD-1 mAb-treated A/J mouse hearts and isotype controls. αPD-1 mAb-treated mice were divided into two subgroups—myocarditis development (αPD-1 myocarditis) and no myocarditis (αPD-1 control). CD8⁺ and CD4⁺ T cells were stained with Myhc_{338–348}-H-2D^d and Myhc_{334–352}-I-A^k tetramers, respectively. (C–F) Gene expression of cardiac-myosin-specific T cells in

mice with α PD-1 myocarditis. Myhc tetramer-positive and -negative cells were FACS from cardiac CD8⁺ (C and E) and CD4⁺ (D and F) T cells.

(G) Representative images of H&E staining on hearts from mice received Myhc-primed or control CD4⁺ donor T cells. All recipients were treated with α PD-1 mAb after T cell transfer. Scale bars: 50 μ m.

(H) Percentage of inflamed area in heart section from mice received Myhc-primed or control CD4⁺ donor T cells.

(I) Number of CD45⁺ infiltrating cells in hearts assessed by flow cytometry analysis.

Pooled data of two or three experiments are shown in (A), (B), and (G)–(I). Representative data of two independent experiments are shown as mean values in (C)–(F). One-way ANOVA with Tukey's test (B) or Student's t test (C–F, H, and I) was used for statistical analysis. * $p < 0.05$; ** $p < 0.005$; *** $p < 0.0005$; **** $p < 0.0001$.




Figure 5. PD-1-expressing cardiac myosin-specific T cells exist in naive A/J mice
 (A and B) Flow cytometry analysis (A) and cell frequencies (B) of cardiac myosin-MHC tetramer-positive cells in CD8⁺ and CD4⁺ T cells of naive A/J mice. Hearts, mediastinal lymph nodes (medLNs), and spleens were examined. CD8⁺ and CD4⁺ T cells were stained with Myhc₃₃₈₋₃₄₈-H-2D^d and Myhc₃₃₄₋₃₅₂-I-A^k tetramers, respectively.
 (C and D) Flow cytometry plots (C) and frequencies (D) of PD-1-expressing cells in Myhc₃₃₄₋₃₅₂ tetramer-positive and -negative CD4⁺ T cells. Cells were isolated from naive mouse hearts, medLNs, and spleens.

(E and F) Flow cytometry analysis (E) and cell frequencies (F) of CD44⁺CD69⁺ cells in PD-1-positive and -negative cardiac-myosin-specific CD4⁺ T cells. Cells were isolated from naive hearts, medLNs, and spleens.

(G and H) Flow cytometry plots (G) and cell frequencies (H) of cardiac myosin-MHC tetramer-positive cells among CD8⁺ and CD4⁺ T cells in the heart of naive young (12 weeks) and aged (44 weeks) mice.

Pooled data of two experiments are shown. Student's t test was used for statistical analysis.

*p < 0.05; **p < 0.005; ****p < 0.0001.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-mouse PD-1 (clone RMP1-14)	Bio X Cell	Cat# BE0146; RRID: AB_10949053
Rat IgG2a isotype control (clone 2A3)	Bio X Cell	Cat# BE0089; RRID: AB_1107769
Anti-mouse CTLA-4 (clone UC-10-4F10-11)	Bio X Cell	Cat# BE0032; RRID: AB_1107598
Purified anti-CD16/CD32 (clone 93)	Thermo Fisher	Cat# 14-0161-86; RRID: AB_467133
BUV563 anti-mouse CD45 (clone 30-F11)	BD Biosciences	Cat# 612924; RRID: AB_2870209
APC anti-mouse Nkp46 (clone 29A1.4)	BioLegend	Cat# 137607; RRID: AB_10612749
FITC anti-mouse CD11b (clone M1/70)	BioLegend	Cat# 101205; RRID: AB_312788
BV785 anti-mouse Ly6G (clone 1A8)	BioLegend	Cat# 127645; RRID: AB_2566317
PE-Cy7 anti-mouse F4/80 (clone BM8)	BioLegend	Cat# 123113; RRID: AB_893490
BV711 anti-mouse CD64 (clone X54-5/7.1)	BioLegend	Cat# 139311; RRID: AB_2563846
Alexa Fluor 700 anti-mouse Ly6C (clone HK1.4)	BioLegend	Cat# 128023; RRID: AB_10640119
BUV395 anti-mouse CD19 (clone 1D3)	BD Biosciences	Cat# 565965; RRID: AB_2739418
PE-Dazzle 594 anti-mouse CD3 (clone 17A2)	BioLegend	Cat# 100245; RRID: AB_2565882
BV421 anti-mouse TCR $\gamma\delta$ (clone GL3)	BioLegend	Cat# 118119; RRID: AB_10896753
BV605 anti-mouse CD4 (clone GK1.5)	BioLegend	Cat# 100451; RRID: AB_2564591
BUV805 anti-mouse CD8 (clone 53-6.7)	BD Biosciences	Cat# 612898; RRID: AB_2870186
BV421 anti-mouse CD62L (clone MEL-14)	BioLegend	Cat# 104435; RRID: AB_10900082
PE-Cy7 anti-mouse CD44 (clone IM7)	BioLegend	Cat# 103029; RRID: AB_830786
BUV395 anti-mouse CD69 (clone H1.2F3)	BD Biosciences	Cat# 740220; RRID: AB_2739968
BV711 anti-mouse PD-1 (clone 29F.1A12)	BioLegend	Cat# 135231; RRID: AB_2566158
BV605 anti-mouse TIM-3 (clone RMT3-23)	BioLegend	Cat# 119721; RRID: AB_2616907
CD4 (L3T4) MicroBeads, Mouse	Miltenyi	Cat# 130-117-043
Chemicals, peptides, and recombinant proteins		
Freund's Adjuvant, Complete	MilliporeSigma	Cat# F5881
Recombinant Murine IL-12p70	PeptoTech	Cat# 210-12
Recombinant Mouse IL-23	Sino Biological	Cat# CT028-M08H
Recombinant Mouse IL-1beta	Sino Biological	Cat# 50101-MNAE
Collagenase, Type 2	Worthington	Cat# LS004177
Deoxyribonuclease I	Worthington	Cat# LS002139
Hyaluronidase	MilliporeSigma	Cat# H3506
Normal Rat Serum	Thermo Fisher	Cat# 31888; RRID: AB_2532178
RNeasy Plus Micro Kit	Qiagen	Cat# 74034
iScript Reverse Transcription Supermix	Bio-Rad	Cat# 7108841
PowerUP SYBR Green Master Mix	Thermo Fisher	Cat# A25742
Critical commercial assays		
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit	Thermo Fisher	Cat# L34966

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Mouse Cardiac Troponin-I ELISA	Life Diagnostics	Cat# CTNI-1-US
DeadEnd Fluorometric TUNEL System	Promega	Cat# G3250
Experimental models: Organisms/strains		
Male A/J mouse	Jackson Laboratory	Cat# 000646; RRID:IMSR_JAX:000646
Oligonucleotides		
Primers for real-time RT-PCR, see Table S2	Integrated DNA Technologies	N/A
Software and algorithms		
FlowJo	BD	RRID: SCR_008520
Prism	GraphPad	RRID: SCR_002798

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript